https://orcid.org/0000-0002-1058-659X
References
- Lindeke-Myers A, Hanif AM, Jain N. Pentosan polysulfate maculopathy. Surv Ophthalmol 2022; 67: 83–96.
- Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol 2015; 193: 1545–1553.
- Patnaik SS, Laganà AS, Vitale SG, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet 2017; 295: 1341–1359.
- Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology 2018; 125: 1793–1802.
- Wang D, Au A, Gunnemann F, et al. Pentosan-Associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. Can J Ophthalmol 2020; 55: 116–125.
- Hanif AM, Armenti ST, Taylor SC, et al. Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study. JAMA Ophthalmol 2019; 137: 1275–1282.
- Abou-Jaoude MM, Davis AM, Fraser CE, et al. New insights into pentosan polysulfate maculopathy. Ophthalmic Surg Lasers Imaging Retina 2021; 52: 13–22.
- Christiansen JS, Barnes AC, Berry DE, et al. Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging. Can J Ophthalmol 2021; 57: 16–22.